A downtrend has been apparent in Cytek Biosciences, Inc. (CTKB) lately with too much selling pressure. The stock has declined 7.3% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indi ...

Shares of Cytek Biosciences, Inc. (CTKB) have gained 0.7% over the past four weeks to close the last trading session at $6.91, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $10.20 indicates a potential upside of 47.6%.The mean estimate comprises five short-term price targets with a standard deviation of $1.10. While the lowest estimate of $9 indicates a 30.3% increase from the ...

dra_schwartz/iStock via Getty Images Introduction Cytek Biosciences (NASDAQ:CTKB) is a leading cellular analysis instrument maker, with a primary focus on industry-leading Aurora flow cytometry platform. The flow cytometry field is mature with the lab instrument manufacturers holding significant market share, but Cytek has built a leading position thanks to offering the highest number of fluorescent detectors. This leads to deeper insights using a full spectrum of fluorescence. This niche leadership has ...

| --- | --- | --- | |---------------------------------------|-----------------------------------------------------------|--------------------| | Name | Title | Date | | /s/ Wenbin Jiang | President, Chief Executive Officer and Director | March 13, 2024 | | Wenbin Jiang, Ph.D. | (Principal Executive Of icer) | | | /s/ Patrik Jeanmonod | Chief Financial Officer | March 13, 2024 | | Patrik Jeanmonod | (Principal Financial and Accounting Of icer) | | | /s/ Ming Yan | Chief Technology Officer and Director | Marc ...

FREMONT, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, announced today that it has opened a new 50,000-square-foot facility in Wuxi, China. This strategic move increases the company's manufacturing capacity to meet the growing worldwide demand for comprehensive cell analysis solutions. The Wuxi facility offers the advantage of fostering unique vendor relationships and further facilitates Cytek to manufacture its own components, d ...

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2023 Earnings Conference Call February 28, 2024 5:00 PM ET Company Participants Paul Goodson – Investor Relations Wenbin Jiang – Chief Executive Officer Patrik Jeanmonod – Chief Financial Officer Conference Call Participants Matthew Sykes - Goldman Sachs David Westenberg - Piper Sandler Tejas Savant - Morgan Stanley Steven Mah - TD Cowen Mason Carrico - Stephens Operator Good day and thank you for standing by. Welcome to the Cytek Biosciences Fourth Quarter 2023 Earn ...

FREMONT, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2023. Recent Highlights Total revenue was $58.6 million, or $58.2 million on a non-GAAP constant currency basis, for the fourth quarter of 2023, representing 21% and 14% increases, respectively, over the corresponding period of 2022 Organic revenue was $48.8 m ...

The market expects Cytek Biosciences, Inc. (CTKB) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected t ...

FREMONT, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences. BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah Participating on Tuesday, February 13th and Wednesday, February 14th Raymond James 45th Annual Institutional Investors Conference in Orlando, FLPresentation on Monday, March 4th at 2:15 p ...

FREMONT, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences. BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah Participating on Tuesday, February 13th and Wednesday, February 14th Raymond James 45th Annual Institutional Investors Conference in Orlando, FLPresentation on Monday, March 4th at 2:15 ...